{
    "cord_uid": "izxhiusf",
    "source_x": "PMC",
    "pmcid": "PMC3420249",
    "divid": "22",
    "text": "Thirty-three children, 12 girls and 21 boys with a median age of 10 months (range 4-38 m), were assessed because of unexplained persistent wheezing despite ICS therapy. Administrated ICS dosages ranged from 100-500 mcg fluticasone daily or equivalent, with a variable treatment duration of 1-10 months. Table 1 summarises the characteristics of the study population with respect to allergy and reflux testing results, and familial and environmental risk factors for asthma. Only 7 of 13 (53.8 %) children suffering from gastro-oesophageal reflux disease (GERD), were treated for GERD prior to FOB + BAL.",
    "project": "cdlai_CORD-19",
    "denotations": [
        {
            "id": "S-scispacy-abbr_T1",
            "span": {
                "begin": 555,
                "end": 559
            },
            "obj": "Abbreviation"
        },
        {
            "id": "S-scispacy-abbr_T2",
            "span": {
                "begin": 579,
                "end": 583
            },
            "obj": "Abbreviation"
        }
    ]
}